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Abstract
Since 2004 there has been an increased recognition of the importance of Neglected Tropical Diseases (NTDs) as
impediments to development. These diseases are caused by a variety of infectious agents - viruses, bacteria and
parasites - which cause a diversity of clinical conditions throughout the tropics. The World Health Organisation
(WHO) has defined seventeen of these conditions as core NTDs. The objectives for the control, elimination or
eradication of these conditions have been defined in World Health Assembly resolutions whilst the strategies for
the control or elimination of individual diseases have been defined in various WHO documents. Since 2005 there
has been a drive for the expanded control of these diseases through an integrated approach of mass drug
administration referred to as Preventive Chemotherapy via community-based distribution systems and through
schools. This has been made possible by donations from major pharmaceutical companies of quality and
efficacious drugs which have a proven track record of safety. As a result of the increased commitment of endemic
countries, bilateral donors and non-governmental development organisations, there has been a considerable
expansion of mass drug administration. In particular, programmes targeting lymphatic filariasis, onchocerciasis,
schistosomiasis, trachoma and soil transmitted helminth infections have expanded to treat 887. 8 million people in
2009. There has been significant progress towards guinea worm eradication, and the control of leprosy and human
African trypanosomiasis. This paper responds to what the authors believe are inappropriate criticisms of these
programmes and counters accusations of the motives of partners made in recently published papers. We provide a
detailed response and update the information on the numbers of global treatments undertaken for NTDs and list
the success stories to date.
The paper acknowledges that in undertaking any health programme in environments such as post-conflict
countries, there are always challenges. It is also recognised that NTD control must always be undertaken within the
health system context. However, it is important to emphasise that the availability of donated drugs, the multiple
impact of those drugs, the willingness of countries to undertake their distribution, thereby committing their own
resources to the programmes, and the proven beneficial results outweigh the problems which are faced in
environments where communities are often beyond the reach of health services. Given the availability of these
interventions, their cost effectiveness and the broader development impact we believe it would be unethical not
to continue programmes of such long term benefit to the “bottom billion”.
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Background
Over recent years, the profile of what are referred to as
Neglected Tropical Diseases (NTDs) has increased as a
result of several developments including increased advo-
cacy for new approaches to the control or elimination of
these diseases, the increased commitment from pharma-
ceutical donors to provide drugs, renewed government
commitment and the recognition that these diseases
should be addressed as part of the Millennium Develop-
ment Goal (MDG) agenda where they are considered as
“other diseases” of MDG 6. Significant commitments in
bilateral resources have been made by the US and UK gov-
ernments, whilst the Director-General of the World
Health Organization (WHO) has emphasised the need for
countries to address these diseases, which afflict poor
populations in the world’s least developed countries. It is
now recognised these diseases are key impediments to
development as a result of their health, educational and
socioeconomic impact. There are a number of World
Health Assembly Resolutions, which mandate WHO and
member states to address control and elimination targets
for specific neglected tropical diseases. WHO reports on a
regular basis to the World Health Assembly on the pro-
gress Member States have achieved. The arguments for
increased resources to address the NTDs was based on the
deliberations of meetings hosted by WHO and Deutsche
Gesellschaft fur Technissche (GTZ - now Internationale
Zusammenarbeit) in 2003 and 2004 [1,2] with the subse-
quent publication of a series of papers advocating for an
integrated approach to their control [3-6]. In the interim,
WHO developed an overarching strategy including guide-
lines for preventive chemotherapy [7] and published in
2010 its First Global Report on Neglected Tropical Dis-
eases [8] entitled “Working to overcome the global impact
of neglected tropical diseases”. A summary of the informa-
tion in the WHO report is available in [9]. Recent peer
reviewed publications [10,11] have been critical of various
aspects of the momentum to advance the health and well-
being of those afflicted with NTDs and have openly criti-
cised the approach to mass drug distribution. These criti-
cisms were based on a limited analysis of case studies in
two countries. This paper provides a response to those cri-
ticisms as they fail to give adequate attention to many
examples of successes in reducing the burden of these dis-
eases in numerous validated and peer-reviewed reports.
The papers [10,11] also fail to cite important references
relating to monitoring and evaluation, sustainability, drug
efficacy studies and health systems research topics, which
are the subjects of critical comments.
Review
Critical and Sceptical Voices
A recent voice of scepticism of NTD initiatives has been
published in Third World Quarterly, 32, 91-117 by Tim
Allen and Melissa Parker in 2011 entitled “The “Other
Diseases” of the Millennium Development Goals: rheto-
ric and reality of free drug distribution to cure poor’s
parasites”[10]. The authors [10] misquote the aim of
MDG 6 by including TB, which is not specifically
included in the formal MDG statement, which reads “to
combat HIV/AIDS malaria and other diseases”. The
paper [10], whilst referring to several pertinent publica-
tions, does not cite or comment on papers in a Lancet
Series on NTDs that offer critical evidence in support of
NTD interventions [12-16]. Nor does it refer to a paper
[17] published in 2008, which addresses the arguments
for investment in NTD control using the title “Other
Diseases” and Millennium Development Goals. These
authors’ non-selection of these references is germane,
since they do, in fact, include an editorial comment
from the Lancet in February 2010 to support their argu-
ments, despite the fact that the commissioned Lancet
Series on NTDs was published the previous month (Jan-
uary 2010) suggesting these papers were ignored. The
Series on NTDs in the Lancet was accompanied by a
peer-reviewed Comment [12] outlining the arguments
for the increased investment in NTD control whilst the
front cover page introducing the Lancet series headlined
the following quote “Only 0.6% of overseas development
assistance for health is allocated to neglected tropical
diseases affecting at least 1 billion people” thereby
emphasising the context. This statement comes from
the analysis by Liese and Schubert [18] on the official
Overseas Development Assistance for health being com-
mitted to NTD control in comparison with other health
development activities.
However, having failed to quote the Lancet Series the
month before, Allen and Parker refer to the Lancet edi-
torial of February 2010 [19] and comment as “excoriat-
ing” implying “excoriating” refers to NTDs although the
editorial was directed at criticism of UNICEF. Allen and
Parker [10] state “but identical observations might soon
have to be made about the current target obsessed
approach to drug distribution for NTD control”. These
authors make several statements in their paper [10],
which need rebuttal in detail, given the available pub-
lished data. Significant papers and current programmes
have not been referred to in any detail nor have the his-
toric and sustained successes of NTD control been
recognised. A summary table of NTD programme suc-
cesses was published [17] and an update is included in
this paper.
Putting progress into context and addressing
misconceptions
Statements made by Allen and Parker [10], however,
need comment as it is suggested that published data are
invalid or inaccurate. There is no doubt that in some
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settings there are problems with reporting; Allen and
Parker are correct to identify such issues, which are
common to all health programmes not just those target-
ing NTDs. However, the impression gained from the
paper [10] is that the WHO published figures are inac-
curate or incorrect. Phrases such as “it is claimed” that
670 million [8,9] people were treated for NTDs via pre-
ventive chemotherapy in 2008 are used in [10] when
WHO, in its normative role, has the obligation to pro-
vide to the international health community the figures
which they are given by Member States. Such comments
[10], throw doubt on the integrity of both the endemic
countries and WHO. Allen and Parker [10] state that
there is a growing body of research that suggests distri-
buting drugs “is facing serious problems”. At no time in
the paper do the authors refer to the successes of pro-
grammes. These NTD successes have been described
[3,17]. Allen and Parker [10] do not refer, for example,
to the successes, of the African Programme for Oncho-
cerciasis Control (APOC), the Leprosy programme, Tra-
choma control, in the Guinea Worm Eradication
Programme, in human African trypanosomiasis activities
and several country successes in lymphatic filariasis. We
summarise these achievements at the end of this paper.
“Active resistance”
Allen and Parker refer to “active resistance” against free
drug treatment programmes.
The evidence from over one hundred projects of the
African Programme for Onchocerciasis Control (APOC)
in 19 African countries, where sustained delivery of iver-
mectin for the control of onchocerciasis, has been
ongoing in hyper- and meso-endemic areas since 1996,
is ignored. This programme is now reaching a popula-
tion of over 68 million with annual treatments and as
drug deliverers at the community level are unpaid, this
hardly suggests “active resistance” [8]. This position is
supported by an APOC evaluation [20] of the sustain-
ability of projects by standard and rigorous evaluation
procedures; the conclusions in [20], undertaken in 492
communities representing 41 APOC projects in 10
countries suggest that coverage and compliance was
higher when no incentives were given to community
distributors. Some 70% of these projects were consid-
ered to be satisfactory or highly sustainable, it was
recognised that weak health systems that resulted in late
delivery of ivermectin could impair sustainability, but
there was no “active resistance”. A recent paper by Brie-
ger et al. [21] directly addresses the issues raised by
Allen and Parker [10] focussing particularly on compli-
ance with community directed mass drug administration
(MDA) and relating the interactions between compli-
ance and coverage in a study in five sites in Nigeria and
Cameroon involving over 8000 participants. Allen and
Parker [10] cite various observations about the resis-
tance to treatment following adverse events in Tanzania
and Uganda. In the APOC programme, partners have
sought to address the serious adverse events, which
occurred in the early part of the programme associated
with the use of ivermectin in communities co-endemic
with the Tropical Eye Worm, Loa loa. In certain areas
of Cameroon and Democratic Republic of Congo (DRC)
treatment with ivermectin resulted in a Loa-induced
encephalopathy in approximately 1 in 10,000 treatments
[22,23]. APOC, the drug donor, Merck & Co. Inc., and
the Mectizan Donation Program immediately took steps
to produce guidelines for the use of ivermectin in areas
of high risk, initiated research on the alternate
approaches and supported the development of mapping
tools to define those high risk areas [24,25]. The pro-
blems associated with expanding MDA for lymphatic
filariasis in areas of potential co-endemicity with L. loa
have delayed implementation in central Africa and the
recent WHO Review document and Strategic Plan for
lymphatic filariasis 2011-2020 considers addressing the
challenge of co-endemic loiasis a priority [26]. This
approach reflects the responsibility of those associated
with NTD control to concerns over safety with the
recognition that continued research is necessary to find
optimal solutions. There is a need to reduce the risk of
adverse events to be balanced with the broader public
health goals of elimination of a public health problem
through risk-benefit analyses.
“Technique Transplantation” - what the evidence actually
says
Allen and Parker [10] refer to the quotation from the
first Director-General of WHO, Dr Brock Chisholm,
regarding “transplanting techniques” and refer to MDA
for NTD control. The issue of technique transplantation
in reference to the current MDA strategies cannot be
classified in such a way. Indeed the whole purpose of
the community directed approach developed by APOC
[27] is community ownership as the core principle,
while MDA for deworming is often led through the edu-
cation sector as opposed to the health sector, or in
emergency and conflict settings through the World
Food Programme or Non Governmental Development
Organisations (NGDOs). The value of Community
Directed Interventions (CDI) for onchocerciasis control
has been demonstrated in a multi-country study [28] as
a means of implementing other health interventions
with particular reference to the increased coverage with
bednets for malaria control and the Home based Man-
agement of Malaria as well as Vitamin A distribution.
The WHO/UNICEF guidelines also provide information
on deworming in Vitamin A programmes as a safe and
cost saving intervention for children. Homeida et al.
Molyneux and Malecela Parasites & Vectors 2011, 4:234
http://www.parasitesandvectors.com/content/4/1/234
Page 3 of 13
[29] identified some 20 additional health activities,
which were undertaken by community directed distribu-
tors (CDDs) in the APOC programme with no remu-
neration; for Allen and Parker to suggest that this
implies “resistance” to participation in such health pro-
grammes is at variance with facts. It is useful to com-
pare the quotes provided by Homeida et al. [29] as they
provide contradictory views about community MDA
compared with those referred to in [10]. In addition, the
distribution of drugs for onchocerciasis and lymphatic
filariasis in Nigeria increased the bednet uptake for
malaria amongst pregnant women who were excluded
from the MDA (because they were pregnant) by nine-
fold [30]. The initial studies on the use and potential of
community based or directed treatment were assessed
in both Africa and India for filariasis drug distribution,
but in India it was found that populations preferred to
receive treatment from the health services rather than
through the communities. This has, however, not
reduced the ability of the filariasis programme in India
to deliver through the health system 292.8 million treat-
ments in 2010 in 165 implementation units out of a tar-
get population of 377 million without any external
support [31]. A further factor ignored by Allen and Par-
ker is the extent of deworming activities promoted by
the World Bank through the education sector and the
role of the Partnership for Child Development in pro-
moting deworming to improve growth and weight gain
[32] (including rapid growth spurts), reduced stunting,
and increased school attendance (decreasing absentee-
ism by 25%) and improved cognitive performance
scores. These are well-defined outcomes of regular
deworming of school age children. Michel and Kremer
[33] reported that as a result of school deworming pro-
grammes in Kenya, worm infection rates fell by 50%.
They identified significant externalities of deworming in
school age children summarised in a recent presentation
by Bundy [34] which emphasises that deworming
through preventive chemotherapy, is an important part
of development strategy, a fact identified by the UN
Special Advisor to the Secretary-General Jeffrey Sachs in
a UN Report identifying “quick wins” towards the
MDGs published in 2004/5 [35] - improved physical
growth and general health, improved learning abilities
and educational opportunities, externalities leading to
long term economic benefits demonstrated by several
authors in different settings [32-37].
Baird et al. [38] have undertaken a prospective study
of deworming carried out in Kenya [33], which began in
1998; they used a new data set which tracked 83% of
treated subjects who are now between 19 and 26 years
old. Subjects had received two to three more years of
deworming than a comparison group. Among those in
employment, earnings were 21% to 29% higher in the
treated group, hours worked increased by 12%, and
work days lost to ill health declined by a third. The
earnings gained were explained by shifts, for instance, in
a doubling of those in manufacturing employment com-
pared to a reduction of those in casual labour. Those
who were self-employed also improved their income sig-
nificantly. Total years enrolled in school, test scores and
self-reported health improved significantly. The authors
conclude that deworming has very high social returns,
with conservative benefit-cost ratio estimates ranging
from 24.7 to 41.6 [38] justifying the conclusions of the
UN Millennium Development Goal report [35]. Simi-
larly, an independent assessment of the cost effective-
ness of mass chemotherapy interventions for
onchocerciasis, soil transmitted helminths (STH) and
lymphatic filariasis [39], as part of the Disease Control
Priority Project showed that these mass preventive che-
motherapy interventions were amongst the best health
buys available as measured in terms of Disability
Adjusted Life Years (DALYs) averted [39]. As onchocer-
ciasis and lymphatic filariasis interventions are also pro-
viding “deworming” drugs the impact on improved
health, productivity and societal benefit to the 887.8 mil-
lion treated people receiving the interventions must be
profound [8] if the studies from Kenya are extrapolated
globally.
In addition, Bleakely [40] has analysed retrospectively
the impact of elimination of hookworm in the southern
states of the US, which started in 1910 supported by the
Rockefeller Sanitary Commission. At that time, some
40% of children were infected with hookworm. Treat-
ment and education campaigns rapidly reduced the dis-
ease. Areas with higher levels of hookworm infection
prior to the campaign experienced greater increases in
school enrolment, attendance, and literacy after the
intervention. No significant contemporaneous results are
found for literacy or occupational shifts among adults,
who had negligible prior infection rates. A long-term
follow-up indicates a substantial gain in income that
coincided with hookworm elimination. There was also
evidence that the return to schooling increased with
elimination [40].
After accusations of “technique transplantation,” Allen
and Parker then state with reference to the “target
obsessed approach” to NTD control that “Monitoring
and Evaluation are systematically inadequate”. This
appears to be a non-sequitor. Target obsession would
surely be related to monitoring and evaluation. The
most recent overview of monitoring and evaluation by
Baker et al. [15] is not quoted by Allen and Parker;
neither do they refer to the detailed data produced by
WHO in the Weekly Epidemiological Record (WER) for
all the NTDs in a systematic way each year or to peer
reviewed publications on several programmes. All up-to-
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date country data are available on line at WHO NTD
sites referring specifically to each NTD disease on an
annual basis, for example [31,41,42] with information on
target numbers and reported coverage where appropri-
ate. In the case of Guinea Worm (Dracunculiasis) the
numbers of reported cases in the remaining endemic
countries are published on a monthly basis with com-
parisons with data from previous years. In addition,
reports from Guinea Worm countries in the state of
pre-certification that have not reported a case for over
the last 12 months are also included [42]. This docu-
mented information is in the public domain and derived
from endemic countries. Other information is available
in peer reviewed journals. To suggest, therefore, as
Allen and Parker do, that “there is much more going on
at the moment than the straightforward presentation of
evidence about NTD control” is not only an inappropri-
ate assertion but also not in accordance with the facts.
The statement suggests the data are “overblown asser-
tions”. Ignoring the use of the word “claim” in [10],
WHO in its latest update published in October 2011
reported global treatments for onchocerciasis (68.7 mil-
lion), lymphatic filariasis (485.2 million), soil transmitted
helminths (314 million) and schistosomiasis (19.9 mil-
lion); hence in total 887.8 million people received Pre-
ventive Chemotherapy [9,43] for elimination and control
of these four NTDs. The figure for soil transmitted hel-
minths includes data reported through school-based
programmes and from the World Food Programme
(WFP), Save the Children, World Concern, Helen Keller
International (HKI) and other NGOs, and there may be
overlapping treatments when individuals receive treat-
ments for more than one disease in a reporting year. On
the basis of these figures, at least one tenth of the planet
is receiving drugs for NTDs. This, in itself, whatever the
opinions of Allen and Parker, is a massive achievement
by endemic countries and their diverse partners. To sug-
gest the figures are “overblown assertions” calls into the
question the veracity of many organisations as well as
the national authorities involved. The criticisms regard-
ing this form of delivery by Allen and Parker fail to
recognise the numbers of deworming treatments and
the value of these activities in educational terms [33,37].
There are few reports that this regular intervention has
evoked the emotive stories or active resistance suggested
by Allen and Parker (page 109).
What is the real burden of NTDs? or anything else!
Allen and Parker consider that the numbers of people
infected with NTDs and the Disability Adjusted Life
Years (DALY) burden calculated and attributable to
NTDs “can be little more than guesstimates”. That
assertion could apply to most of the DALY estimates for
almost all diseases and conditions. The NTDs are
caused by a spectrum of different biological agents-
viruses to worms and the resulting clinical conditions
are equally diverse, some being rapidly and inevitably
fatal if untreated, others causing life-long disablement.
However, from the perspective of DALY burden, the cri-
tical issue is the value of disability weights attributed to
these diseases and their true prevalence. In addition
some NTDs cause cancers, (food- borne trematodes and
schistosomiasis), epilepsy (cysticercosis) or injuries (by
dog bites caused by rabies) and such outcomes are not
attributed to NTDs [44]. The current estimates of NTD
annual mortality is circa 500,000 [5,6,8]. Whilst this fig-
ure is an estimate, it must be borne in mind that NTDs,
as causes of death in rural settings in the developing
world, are dependent on quality reporting from periph-
eral health units where diagnosis, even if a death is
reported, is unlikely to be attributed to an NTD as
reporting forms do not necessarily identify particular
NTDs; this particularly applies to the zoonotic NTDs or
Neglected Zoonotic Diseases [44]. What can be said is
that in terms of annual mortality NTDs are broadly the
same as the estimated numbers of maternal deaths,
reducing maternal mortality being a specific MDG.
Impact of MDA via Preventive Chemotherapy on clinical
disease
In reference to the reported studies undertaken by Allen
and Parker in Tanzania [10] regarding the use of iver-
mectin and albendazole on the impact on clinical dis-
ease, they state that the drugs “did not appear to have
an impact” on cases of hydrocele and lymphoedema. In
some cases patients are indeed in an advanced clinical
state, precluding any chemotherapeutic or surgical inter-
vention which would impact on their condition. How-
ever, the authors [10] do not record the sample size of
the people interviewed as there are several published
reports in Tanga and Morogoro, Tanzania of post MDA
improvement in clinical condition-reduction of filarial
fevers or homa za mitoki [45,46]
However, the Global Programme to Eliminate Lym-
phatic Filariasis (GPELF) [31] is designed as a preventive
chemotherapy programme in parallel with a lymphoe-
dema management programme. In Tanzania a Presi-
dent’s Fund has been established to enable patients to
access hydrocele surgery. Morbidity programmes have
often lagged behind the MDA as a component of the
GPELF. However, there is strong evidence that the
drugs used in the LF programme do reduce the fre-
quency of filarial fevers (dermato-lymphangioadenitis),
and, if given early enough, “are capable of reversing the
sub-clinical lymphatic damage in children and provide
other benefits other than the interruption of transmis-
sion” [47], whilst in Papua New Guinea [48] state “Mass
drug administration...results in immediate health
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benefits by decreasing the incidence of acute attacks of
leg and arm in people with pre-existing infection.” They
state, “Results of our study indicate that mass distribu-
tion of anti-filarial drugs has immediate clinical benefit
to endemic communities in addition to future transmis-
sion cessation”. These studies directly contradict the
assertions of Allen and Parker that clinical benefits do
not accrue from MDA whilst there is proven reversal of
pathology in schistosomiasis in 90% of patients treated
with a single dose of praziquantel after 6 months [49,50]
and a reduction in itching (pruritus) after treatment
with ivermectin [8,21].
Addressing criticisms of countries - a case of
neocolonialism?
For its evidence, the study [10] focuses on case studies
in two African countries. The major concern here is
that the methodology in some of the areas is flawed but
nevertheless has resulted in the authors drawing gener-
alized conclusions about country NTD programmes. It
is important that the criticisms leveled at countries are
also addressed.
For example, the authors have focused on Tanzania as
one of their case studies but we express considerable
concern on the methodology used, particularly in the LF
programme, where no attempts were made to gather
information at the regional and national levels. It is
interesting to note that the region which contains dis-
tricts that Allen and Parker [10] describe as their study
sites in Tanzania is one that has a robust monitoring
system for LF and which, since 2004, has been monitor-
ing infection in humans as well as infection and infectiv-
ity in mosquitoes. There have also been coverage
surveys that have been reported, but no reference to
these is made whilst [10] emphasizes that there is no
monitoring and evaluation (M & E) of these pro-
grammes. The published study from Kiarare [51], the
sentinel site for the Tanga region was not referenced.
This is all the more surprising given Kairare in Pangani
district is one of the sites quoted by Allen and Parker
[10].
Allen and Parker quote that “In Tanzania there is a
persistent practice of increasing treatment numbers as
reporting was passed up the system”. This is an asser-
tion that needs to be supported with evidence and using
the data at village, ward, district, regional and national
levels. There is no reference to these additional levels in
the Allen and Parker text. It is important to stress this
because the paper makes reference to exaggerated fig-
ures but does not look at the whole structure of the
health reporting system and the checks and balances
which are embedded at each level. Data from Tanga
region in Tanzania do not show the 100% coverage that
is referred to, and information from the monitoring site
in Kiarare shows clearly that the coverage is not and
never has been 100% [51]. If the researchers had probed
further they would have noted that no regional LF coor-
dinator would accept a figure of 100% and that such a
reported result would have been referred back for
verification.
Allen and Parker go to some lengths to explain how
people call elephantiasis by different names and hence
cannot make the linkage between the disease, its vector
and eventually the MDA. The issue of nomenclature is
something that is well known and earlier studies by
Gasarasi et al. [52] have shown this. Had the authors
critically reviewed the IEC material written in Kiswahili,
focusing on the local terms for the disease, they would
have noted that this was a fact that was taken into con-
sideration in the development of these IEC materials.
Further south they would have encountered several dif-
ferent names for the same conditions. It is important to
state that Allen and Parker worked in a district of
44,107 people (Pangani) and 279,423 (Muheza); from
this experience they inferred their results were applic-
able to the whole country. There is no mention of the
limitations of such inferences and no mention of the
ecological and social heterogeneity of Tanzania which
the authors are fully aware of.
Of serious concern, however, are the factual errors
which call into question the credibility of the authors
and the case studies which are published to support the
authors’ claims [10]. The work in Tanzania refers to an
integrated programme which was not in place until
2009. The references to an NTD programme in Tanza-
nia are erroneous. The reference to the riots in Moro-
goro being the reason for the slow pace of the NTD
programme is not supported by the facts. Negotiations
for programme implementation began in 2004. There
was a consensus building process that involved the lym-
phatic filariasis, onchocerciasis, schistosomiasis, soil
transmitted helminth and the trachoma programmes.
The authors should have made reference to the process
that led to the formation of the integrated NTD pro-
gramme in 2009.
The paper [10] combines events in Tanzania and
Uganda. For example, the statement “drugs are distribu-
ted by district vector control officers”. This is not the
case in Tanzania where the District LF coordinators and
more recently NTD coordinators are involved in the
delivery of the drugs. Issues are lumped in a manner
that suggests what is happening in Uganda is considered
to be the same in Tanzania. Such comments allow gen-
eralizations that are over- simplistic and fail to take into
account country structural differences.
However, we recognize that Allen and Parker [10]
(pages 101-102) do make valid comments and raise per-
tinent questions, which need to be addressed by NTD
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programmes. These include; 1) what proportion of chil-
dren living in endemic areas attend school when school
based programmes are used?, 2) what proportion of
children who do not attend school receive drugs?, 3)
what proportion of adults receive drugs from MDA?, 4)
how are these free drugs perceived by adults and by
children?, 5) are they being swallowed?, 6) do local
understandings of the disease affect consumption?, 7)
are there any indications that individuals are becoming
more aware of the benefits of treatment? The answers
to several of these questions have indeed been addressed
in attempts to determine the target populations and
assess the total coverage of the population. The groups
of people who are not eligible suggest that overall cover-
age of between 65-75% is an acceptable level. Reported
coverage is backed up in some programmes by spot
checks referred to as surveyed coverage. The availability
of free drugs and the perception of benefit are borne
out by the sustained levels of coverage on the one hand
[20,21,31] whilst the actual swallowing of tablets is
assured by a directly observed treatment approach in
some national programmes. As far as awareness of ben-
efit is concerned, the sustainability studies and the
recognition of clinical benefit have been recorded in
[20,21,45-48].
Inappropriate tone of criticism
Several authors appear to have induced exasperation by
“grandstanding rhetoric” and “exaggerated claims”. This
paper seeks to refute such inappropriate comments in a
respected journal. The suggestion that “achievements”
are “purported” is a serious allegation which requires to
be challenged in the public domain. Those individuals
and organisations, including the Director-General of
WHO, have been misrepresented in motive and accused
of the use and presentation of selected data. There is
overwhelming evidence of massive achievements, which
have produced documented health and economic bene-
fits, strong country commitment, pharmaceutical dona-
tions of billions of treatments and proven successes
[8,9,12,17]. It is indeed time to separate rhetoric from
reality. The paper [10] is highly subjective, using exam-
ples from limited field studies and failing to quote or
deliberately ignoring the body of literature, which sup-
ports the arguments for NTD control as a massive con-
tribution to the health of the poorest. NTD
interventions are highly cost effective and cost beneficial
interventions [16,39] - it is indeed time to examine
reality.
Drug resistance and/or reduced efficacy
Reality is not served by ignoring the issues of potential
loss of efficacy or drug resistance; nor is the need for
new products for those diseases where, for many
decades, tools have been inadequate such as human
African trypanosomiasis, Chagas’ disease and leishma-
niasis. The need for effective diagnostics as well as tools
for monitoring and surveillance remains for many
NTDs. Indeed organisations such as the Drugs for
Neglected Diseases Initiative (DNDi) and, the Founda-
tion for Innovative Diagnostics (FIND) have been estab-
lished to address these issues. WHO in response to
concerns about potential drug resistance from albenda-
zole, commissioned an independent multi-country study
to assess the efficacy of the drug against hookworm and
other intestinal parasites [53] and found no evidence of
lack of efficacy in hookworm. The NTD community is
profoundly aware of the need for vigilance. However, to
suggest that the NTD community is unaware of these
needs is incorrect. The research plans for individual pro-
grammes have been published, for example [26,54], and
the deficiencies in our research knowledge emphasised
by WHO [8]
The Allen and Parker paper refers to the Financial
Times letter of Professor Bruno Gryseels. His warning
that there are risks of drug resistance are recognised, as
WHO has undertaken and supported efficacy studies on
albendazole [53] and it is recognised that there is some
evidence of loss of efficacy of ivermectin in some popula-
tions in Ghana [55]. However, this is in a restricted area
and alternative approaches such as doxycycline antibio-
tics targeting the Wolbachia endo-symbiont bacteria
could be deployed in these areas and elsewhere [56,57].
Gryseels et al. [58] warned of the risk of praziquantel
resistance in an outbreak of Schistosoma mansoni in
Senegal which resulted in the drug being used less than
the public health situation demanded. Fenwick et al. [59]
review the evidence for resistance to praziquantel in dif-
ferent settings and, while there is evidence of loss of effi-
cacy in some studies, it appears that true genetic
resistance has not been detected. The suggestion that
praziquantel is withheld as a public health tool on the
basis of possible resistance is not an acceptable position.
NTDs and the Health System
In a recent paper, Cavalli and colleagues [11] described
the interactions between the Neglected Tropical Disease
Control Programme in Mali and the Health System. The
paper makes the valid point that Global Health Initia-
tives (GHIs), of which there have been many emerging
over the past decade [60], have the potential for distor-
tion of the overall needs of the health of the population
and detract from the provision of the necessary care
and, in the process, “burden” the health system. It is
appropriate to respond to various points raised in the
light of the policy debate and the review of the Millen-
nium Development Goals in relation to diseases of pov-
erty and the health MDGs generally.
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In criticising the Mali NTD programme and being
necessarily selective in the regions and districts studied
the paper [11] analyses the first year of activities of the
NTD programme. It is well known that any project has
up-front higher start-up costs than occur in subsequent
years. What is not recognised is that the training of trai-
ners has a multiplier effect in energising health care
‘beyond the end of the road’ in areas where populations
frequently have no access to any government service; it
seems unethical to allow communities to remain disen-
franchised from any health care if donated products are
available with wide spectrum efficacy and can be deliv-
ered at low cost [16]. Health care must start somewhere
and, as APOC has demonstrated, when some 50% of the
treatments of ivermectin are distributed to communities
more than 20 km from any health facility [61] the argu-
ment that NTD programmes do not strengthen but
detract from the development of the health systems fails
completely. If there is no health system it is impossible
to strengthen it. Recent APOC reports suggest that not
only are APOC projects sustainable [20,21] but that the
numbers of health workers and community-directed dis-
tributors who have been trained exceeds 450,000 [61] a
significant contribution to strengthening health systems.
Cavalli et al. [11] fail to recognise that disease control
activities are an integral part of the health system and
should never be separated from it as the proponents of
the Cavalli et al. view seem to believe [58]. This argu-
ment applies to every programme where the target is an
infectious agent, as the overall objective of any pro-
gramme for infectious disease control, elimination or
eradication, is to reduce incidence, be it through vacci-
nation, mass drug distribution, vector control or case
finding and treatment. The objectives of disease control
activities must also be seen in the light of biological fea-
sibility as well as in a public health and policy context.
Authors critical of the preventive chemotherapy
approach [10,11,58] seem not to recognise that many
millions of people in Africa (and in Asia and Latin
America) have benefitted and will continue to benefit
from NTD programmes. The argument of Cavalli et al
[11] is that these programmes damage the health sys-
tem. The latest figures for Africa show that 68 million
are treated annually for onchocerciasis [61] (2010), 82
million for lymphatic filariasis in 2010 [30] in 19 ende-
mic countries and 37 million for trachoma in 19 coun-
tries, the majority being in Africa [62]http://www.who.
int/blindness/publications/GET15REPORT4.pdf. The
drugs used for preventive chemotherapy of onchocercia-
sis and lymphatic filariasis also benefit populations
because of the synergistic impact on intestinal worms
[4,12,17]. These programmes have the objective of
reduction of morbidity and thereby the prevention of
blindness or long-term disability. The fundamental
question for those that suggest that preventive che-
motherapy programmes should await the strengthening
of health systems or resources deployed to strengthen
such systems is simple. Would they countenance and
take responsibility for allowing the risk of blindness and
disability to continue when free drugs are available
which are effective and prevent long term sequelae of
intense infections? Such a position is unethical and
counter to the Right to Health and the WHO Charter.
Strengthening health systems is a laudable objective but
a long-term one. In the meanwhile, MDA can be deliv-
ered by the communities themselves or through schools
at costs that have been assessed to be in cents rather
than dollars per person treated per year [see summary
of papers in [16]. Indeed annual deworming in Asia has
been costed at around US$ 0.02-0.04 [63]. The cost
effectiveness of the lymphatic filariasis programme,
annual deworming and the onchocerciasis programmes
based on ivermectin have been independently assessed
to be amongst the most cost effective public health buys
as a part of the extensive Disease Control Priorities Pro-
ject [39]. If we fail to deliver what we have now and
await the development of stronger health systems then
many poor people will become blind, stigmatised and
disabled both physically and mentally. Nor are we aware
of the impact of NTDs on the mental health of sufferers
and their carers. This remains to be quantified in terms
either of numbers or burden. The issue of the mental
health burden of NTDs together with neglected zoonotic
diseases, (some of which are included by WHO in its
categorisation of NTDs), are two examples of outstand-
ing issues on the NTD agenda to be addressed [44], and
add a further dimension of neglect and underestimated
burden.
Conclusion
Allen and Parker imply the advocates of picking what
has been described as “low hanging fruit” [17] are some-
how misguided, have questionable motives and misre-
present results. These are assertions we address by
providing evidence from the peer reviewed literature,
from historic successes of NTD control strategies when
they are applied, sometimes at a vast scale and provide
references to counter incorrect and invalid assertions.
We also refute specific criticisms from the country per-
spective. There is no doubt that there remains much to
be addressed and a series of papers commissioned by
the WHO Special Programme for Research and Training
on Tropical Diseases (TDR) point out the issues relating
to the social science research needs [64]. Parker and
Allen provide a further critique of the NTD pro-
grammes in Uganda [65]. Justifiably there will be
ongoing debate on the issues surrounding all aspects of
NTDs from a policy context to the scientific priorities
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for individual diseases. However, it is inappropriate to
question the motives and the integrity of individuals on
the one hand and to challenge the right of national gov-
ernments to act as they wish on the other. Our position
is clear - it would be unethical not to distribute to as
many as possible, donated, quality, safe (albeit within
limits specified by the manufacturers and with ongoing
monitoring) and efficacious drugs with a broad impact
on the lives of poor people. These drugs prevent dis-
ablement, reduce the risk of progression to irreversible
disability (skin disease, blindness, gross lymphoedema,
hydrocele and bladder cancer), and can reverse symp-
toms of early pathology (e.g. anterior segment eye
pathology and initial trachoma lesions, lymphatic
damage and associated fevers). They also enhance edu-
cational performance, improve female and maternal
health and birth outcomes [6,8] and potentially reduce
risks of HIV transmission [66]. This indeed is “low
hanging fruit” which it is appropriate to pick; to reject
this position seems unethical and grossly negligent.
Similarly we refute the views of Cavalli et al. [11] who
consider that NTD programmes detract from the prior-
ity, which they perceive should be the strengthening of
health systems. Cavalli et al [11] consider that NTDs, as
well as other vertical programmes, distract health staff
in systems with limited resources from the routine
responsibilities of care. However, an opposite view is
that such programmes strengthen systems in a number
of ways, are ethically appropriate given the role of com-
munities in distribution, the role of community distribu-
tors in providing other health interventions [28,29], the
limited access that such communities have to the health
system (if they have access at all) and an obligation to
provide products, which prevent disability on a huge
scale. To take a contrary view is counter to the “Right
to Health”. We would ask a simple question in response
to Cavalli et al [11] as the paper is based in Mali; would
it be acceptable NOT to distribute ivermectin or azi-
thromycin to communities where there was a severe risk
of blindness when free drugs and other resources were
available, which if they were not given would commit
many thousands of people, including children, to a life
of misery - in the case of onchocerciasis progression to
severe itching, to irreversible posterior segment ocular
lesions with resulting blindness, which could never be
resolved even in the most sophisticated health system!!
In the case of trachoma it would commit children to the
pain and distress of trichiasis and the need for later sur-
gery at high cost. Prevention of such tragedies is the
only alternative when there is no cure and entirely in
accord with the principles of primary health care.
Allen and Parker [10] focus on the major policy
debate at a global level but are disrespectful to endemic
countries. The problems of under and over reporting
are issues that countries are tackling everyday; a pro-
blem not only for NTD programmes. Obtaining good
data from any field programme is a problem, which no
one disputes; hence the application of spot check sur-
veys to ascertain the reported surveyed coverage. No
country, would accept that their system is perfect but
should countries stop such NTD programmes until such
data systems are robust? Is it fair or ethical that such
cheap and effective interventions are denied the poor
when delivery is possible at grassroots level and beyond
existing health services? The tone of the paper [10] is
contradictory. The fact that it questions the motives of
the international communities and partnerships, authors
and advocates as well as the endemic countries, which
hitherto have not prioritized these diseases is not only
damaging but irresponsible; worst it is damaging to
poor people who benefit. The further contradiction is
the accusation that NTD proponents are “target
obsessed” and then accuse NTD programmes of inade-
quate monitoring evaluation, which is illogical. More
constructive and appropriate responses to the issues
confronting NTD control and health systems derive
from papers by Marchal et al. [67] and Utzinger et al.
[68] where a more balanced and measured assessment
of the programmatic complexities are analysed. How-
ever, NTD programmes seem to be the target of such
analyses and are often considered as some kind of “par-
allel” system despite countries themselves considering
them to be a totally appropriate activity for a health sys-
tem and a core part of their function. This position is
anomalous when equal and indeed even stronger criti-
cism can be levelled at the Global Fund for AIDS, TB
and malaria and the polio eradication programme.
These programmes which have also been accused of dis-
torting country priorities [17] do so to an extent far
greater than any NTD programme given the volume of
resources committed to the “big three” [17].
We consider that we cannot wait for health systems to
improve. Indeed NTD control provides the very plat-
form on which they can be built [69]. This paper rejects
and refutes the sentiments expressed by Allen and Par-
ker and Cavalli et al. [11] and provides detailed
responses to their assertions and claims by referencing
peer reviewed publications on NTDs not referenced by
them and providing references to data from many coun-
tries where NTD control is a part of country health pro-
grammes. The section below provides a summary of
some of that information.
Selected successes in the Control of Neglected Tropical
Diseases
The Allen and Parker paper [10] on page 94 asks two
questions; “Can they [NTDs] be so readily controlled
and what has been achieved so far? Our answer to the
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latter two questions is that, perhaps not surprisingly,
things are very much more complicated than is
claimed”. Below are documented accounts of the suc-
cesses of NTD programmes, which refute the suggestion
that NTDs cannot be readily controlled.
Lymphatic Filariasis has been successfully controlled
in China in a population of 350 million people and in
the Republic of Korea (South Korea); transmission has
also been arrested in several countries where it is no
longer a public health problem [54]. WHO [31] has
reviewed the status of 9 countries originally classified as
endemic but found not to require MDA (Burundi, Cape
Verde, Costa Rica, Mauritius, Rwanda, Seychelles, Solo-
mon Islands, Suriname, and Trinidad and Tobago) as
there was no evidence of transmission [31]. However,
Egypt [70], Togo, Yemen, Cambodia, Vietnam, Maldives,
Sri Lanka and 7 Pacific Island nations who implemented
MDA early in the programme have reduced transmis-
sion and met the criteria of stopping MDA. These coun-
tries require transmission assessment surveys as
recommended by WHO. WHO has reported that
around 500 million treatments are being distributed
each year [26] with savings of US$ 24 billion between
2000-2008 [71]. Annual treatments of ivermectin and
albendazole are given in Africa where onchocerciasis is
co-endemic. In the rest of the world the drugs used are
diethylcarbamazine (DEC) and albendazole. Ivermectin
and albendazole also have a significant impact against
intestinal worms. As a result of the programme up to
2008, 66 million newborns have been prevented from
becoming infected, 2.2 million protected from develop-
ing clinical disease and 28.7 million who have problems
of existing infection have seen their clinical symptoms
diminish and not progress to further disability. The
most recent data from WHO [31] reported that by the
end of 2010, 53 countries had implemented drug distri-
bution programmes of the 72 now recognised endemic
countries. Country data reported to WHO for 2010
showed that 622 million people had been targeted for
MDA and 466 million had been treated giving a
reported coverage of 75%. However, several countries
are yet to initiate MDA in Africa.
River Blindness (onchocerciasis) has been eliminated
as a public health problem and as a disease of socio-eco-
nomic importance in 10 West Africa countries, the ori-
ginal area of the Onchocerciasis Control Programme
(OCP) protecting a population of some 50 million peo-
ple; the benefits of the OCP have been quantified as
600,000 cases of blindness prevented, 18 million born
free of the risk of blindness, 25 million hectares of ara-
ble land reclaimed for settlement and agricultural pro-
duction. This programme which started in 1974 and
continued with uninterrupted donor support until 2002
has been widely recognised as one of the most
successful health and development programmes ever
executed both in terms of health and development gains
but in terms of World Bank investment [72]. Control of
blindness and skin disease via the donated drug iver-
mectin (Mectizan; donated by Merck & Co. Inc) is now
reaching over 68 million people each year in 17 coun-
tries by the APOC supported by national governments
and Non Governmental Development Organisations
through over 748,000 community workers trained in
120,000 communities since 1995. In Africa there is evi-
dence that 15-17 years annual distribution of ivermectin
has eliminated transmission in Mali and Senegal [73]
providing strong evidence that elimination is possible
with ivermectin alone. Onchocerciasis is also endemic in
6 countries in Latin America where twice yearly distri-
bution of ivermectin has arrested transmission in 4 foci.
in Colombia, Guatemala and Mexico and interrupted
transmission in a further 6 other foci [74].
Domestic transmission of Chagas disease due to Try-
panosoma cruzi has been controlled in five South Amer-
ican countries by domestic spraying of insecticide
against the vector Triatoma infestans, providing eco-
nomic rates of return of around 30% on the investment
in vector control. In Central America, progress has been
reported through control of Rhodnius prolixus. Trans-
mission by blood transfusion has been substantially
reduced throughout Latin America. Sustaining the
advances made and maintaining an effective surveillance
system are necessary whilst research for new and effec-
tive drugs continues to be a high priority to treat those
infected.
Leprosy has been reduced as a public health problem
as a result of the use of multidrug therapy of three
donated drugs- rifampicin, dapsone and clofazimine. Of
the 122 countries considered endemic for leprosy,
WHO states that 119 have eliminated the disease as a
public health problem (defined as 1 case per/10,000).
The 213,000 cases reported are confined to 17 countries
reporting more than a 1000 cases/year. The figures sug-
gest a reduction of 90% in endemic countries through
case finding and multidrug therapy, which have pre-
vented disabilities in between 1 and 2 million people.
Since 1985 some 14.5 million people have been cured
through multidrug therapy. The numbers of new cases
per year have fallen dramatically [8,41].
Guinea Worm is moving towards eradication. The
numbers of cases have been dramatically reduced from
over 1 million in 1988 to 1797 in 2010 [42]; countries
with ongoing indigenous transmission are Chad, Ethio-
pia, Mali and Sudan. There are several countries, which
have not reported cases during the previous year (Bur-
kina Faso, Cote d’Ivoire, Ghana, Kenya, Niger, Nigeria,
Togo) and are considered to be in the pre-certification
phase awaiting formal certification as being free of
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transmission. Post-certification, there is a continued
need for surveillance until global eradication is declared.
The Weekly Epidemiological Record (WER) of WHO
provides monthly reports on data from the remaining
endemic countries and those yet to be certified as free
of transmission - the pre-certification countries. The lat-
est WER reporting all the country data reported to
WHO from 2010 can be found in [42].
Schistosomiasis affects some 200 million people.
Intensive control in Egypt has reduced prevalence from
around 20% to less than 1-2% using the drug praziquan-
tel (now 0.32 US$/treatment) over the last two decades
of both S. mansoni and S. haematobium [59]. Schistoso-
miasis transmission in Egypt has been largely eliminated
over the last five years and control focuses on hotspots
of transmission and the result has been a massive reduc-
tion in incidence of bladder cancer. China has also made
considerable progress and now there are less than 1 mil-
lion people reported to be infected [75]. Programmes in
Africa are now reaching school age children in 17 coun-
tries in Africa and initial results show that dramatic
reduction in prevalence over a period of 4 years of
annual treatment.
A Trachoma programme has been established to
eliminate blinding trachoma by 2020 through the SAFE
strategy (S = surgery; A = antibiotics; F = facial cleanli-
ness through washing; E = environmental control). Tra-
choma is endemic in 57 countries and the cost of the
disease in terms of lost productivity is estimated at US$
2.9-5.3 billion/annum. The antibiotic azithromycin
(Zithromax) is donated. Three countries have reported
reaching their ultimate intervention goal targets (Iran,
Morocco and Oman). There is a need for further
upscaling in the highest burden countries such as Ethio-
pia, Nigeria and Sudan. There were 37 million treat-
ments of donated zithromax in 19 countries in 2010
[62].
Human African Sleeping Sickness. Over the period
1999-2009 the numbers of reported new cases of both
Trypanosoma brucei rhodesiense and T. b. gambiense
sleeping sickness has declined by 65%, the numbers of
new cases reported falling from over 28,481 to 9,878.
However, these figures are likely to be underestimates
because of the remoteness of many endemic areas that
may not be covered by regular surveillance. There is evi-
dence that the disease is no longer present in many
West African countries probably due to climate change
and population pressure on habitat of the tsetse fly vec-
tor, Glossina. The problem remains focussed in Central
Africa. In 2009 only 2 countries reported over 1,000
cases - DRC and Central African Republic followed by
Chad (510 cases), Sudan (376) and Angola (247) - of T.
b. gambiense; more extensive surveillance and the avail-
ability of treatment provided through WHO of donated
drugs is the likely cause of the reduced incidence
reported. There remains a need to maintain effective
surveillance in historic foci and provide diagnostic tests.
There has also been a reported decline in cases of acute
T. rhodesiense of 58% in East and Southern Africa 1999-
2009, from 619 to 190, a 70% decrease http://www.who.
int/gho/neglected_diseases/human_african_trypanoso-
miasis/en/index.html. The adoption of a cattle treatment
and insecticide spraying of cattle as a strategy to reduce
the reservoir of human infective parasites in Uganda has
had a major impact on transmission of T. rhodesiense to
humans [76].
Soil transmitted helminth control targets three
nematode worms, which inhabit the gut; hookworm
(Necator and Ancylostoma), whipworm (Trichuris) and
roundworm (Ascaris) and whose global prevalence is
probably greater than all the other NTDs combined.
Some 882 million children are estimated by WHO [77]
to need preventive chemotherapy (273 million pre
school age and 609 million school age). WHO reported
that 109.7 million pre-school children (proportion of
total 33.7%) and 204 million school age (proportion
29.9%) were treated. The overall coverage around 30% is
below the global target number treated, which was 313.7
million in 2009, an increase of over 100 million since
2008. Annual mass drug distribution of the drugs
mebendazole or albendazole through deworming pro-
grammes usually by school-based delivery have a signifi-
cant impact on educational achievement, increased
growth and weight gain, cognitive and physical perfor-
mance [32,36,37]. Deworming of pregnant women in
the second and third trimester of pregnancy increased
child survival at the age of 6 months by over 40% in
areas of hookworm endemicity. The costs of these
deworming programmes in South East Asia are of the
order of 2 US cents/year [63]. The onchocerciasis and
lymphatic filariasis programmes also act as deworming
programmes as the drugs used have powerful effects on
the worms of the gut.
Acknowledgements
We are grateful to Dr Lorenzo Savioli, Director of the Department for the
Control of Neglected Tropical Diseases, World Health Organisation, Geneva
and his staff for their comments and in verifying the figures quoted in this
paper and to Mr Ken Gustavsen of Merck & Co. Inc. for his helpful
comments on the manuscript as well as two anonymous referees who
made most useful suggestions.
Author details
1Centre for Neglected Tropical Diseases, Liverpool School of Tropical
Medicine, Pembroke Place, Liverpool, L3 5QA, UK. 2National Institute For
Medical Research, Ocean Road, P.O Box 9653, Dar-es-Salaam, Tanzania.
Authors’ contributions
DHM wrote the initial draft. MM contributed specific information about the
Tanzania NTD activities. Both authors read and approved the final
manuscript
Molyneux and Malecela Parasites & Vectors 2011, 4:234
http://www.parasitesandvectors.com/content/4/1/234
Page 11 of 13
Competing interests
David Molyneux is, in part, supported by a grant to the Liverpool School of
Tropical Medicine, Centre for Neglected Tropical Diseases, from the UK
Department for International Development and GlaxoSmithKline.
Received: 2 November 2011 Accepted: 13 December 2011
Published: 13 December 2011
References
1. World Health Organisation: Intensified control of neglected diseases:
report of an international workshop. Berlin, 10-12 December. WHO/CDS/
CPE/CEE/2004.45 2004 Geneva; 2003.
2. World Health Organisation: Strategic and technical meeting on intensified
control of neglected tropical diseases: report of an international
workshop, Berlin 18-20 April 2005. WHO/CDS/NTD/2006.1 Geneva; 2006.
3. Molyneux DH: “Neglected” diseases but unrecognized successes -
challenges and opportunities for infectious disease control. Lancet 2004,
364:380-383.
4. Molyneux DH, Hotez PJ, Fenwick A: “Rapid-impact interventions": how a
policy of integrated control for Africa’s neglected tropical diseases could
benefit the poor. PLoS Med 2005, 2:e336-e336.
5. Hotez PJ, Molyneux DH, Fenwick A, Ottesen E, Ehrlich Sachs S, Sachs JD:
Incorporating a rapid-impact package for neglected tropical diseases
with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med 2006, 3:
e102.
6. Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Sachs SE, Sachs JD,
Savioli L: Control of Neglected Tropical Diseases. New Eng J Med 2007,
357:1018-27.
7. World Health Organisation: Preventive chemotherapy in human
helminthiasis. Coordinated use of anthelminthic drugs in control
interventions: a manual for health professionals and programme
managers. Geneva; 2006 [http://whqlibdoc.who.int/publications/2006/
9241547103_eng.pdf].
8. World Health Organisation: Working to overcome the global impact of
neglected tropical diseases. WHO/HTM/NTD/2010.1 Geneva; 2010.
9. World Health Organisation: Weekly Epidemiological Record - Working to
overcome the global impact of neglected tropical diseases - Summary.
Wkly Epidemioll Rec 2011, 86:113-128.
10. Allen T, Parker M: The other diseases of the Millennium Development
Goals: rhetoric and reality of free drug distribution to cure poor’s
parasites. Thd Wld Quar 2011, 32:91-117.
11. Cavalli A, Bamba SI, Troare MN, Boelaert M, Coulibaly Y, Polman K, Pirard M,
Van Dormael M: Interactions between Global Health Initiatives and
Country Health Systems: the case of neglected tropical diseases control
program in Mali. PLoS Negl Trop Dis 2010, 4:e798.
12. Molyneux DH: Neglected Tropical Diseases-beyond the tipping point?
Lancet 2010, 375:3-4.
13. Liese B, Rosenberg M, Schratz A: Programmes, partnerships, and
governance for elimination control of neglected tropical diseases. Lancet
2010, 375:67-76.
14. Gyapong J, Gyapong M, Yellu N, Anakwah K, Amofaf G, Bockarie M, Adjei S:
Integration of control of neglected tropical diseases into health care
systems: challenges and opportunities. Lancet 2010, 375:160-165.
15. Baker MC, Mathieu E, Fleming FM, Deming M, King JD, Garba A, Koroma JB,
Bockarie M, Kabore A, Sankara D, Molyneux DH: Mapping, monitoring and
surveillance of neglected tropical diseases: towards a policy framework.
Lancet 2010, 375:231-238.
16. Conteh L, Engels T, Molyneux DH: Socioeconomic aspects of neglected
tropical diseases. Lancet 2010, 375:239-247.
17. Molyneux DH: Combating the “other diseases” of MDG 6: changing the
paradigm to achieve equity and poverty reduction? Trans Roy Soc Trop
Med Hyg 2008, 102:509-19.
18. Liese B, Schubert L: Official development assistance for health-how
neglected are neglected tropical diseases? An analysis of health
financing. Int Hlth 2009, 1:141-147.
19. Lancet: Editorial Evaluation: the top priority for global health. Lancet
2010, 375:526.
20. Amazigo U, Okeibunor J, Matovu V, Zouré H, Bump J, Seketeli A:
Performance of predictors: evaluating sustainability in community-
directed treatment projects of the African Programme for
Onchocerciasis Control. Soc Sci Med 2007, 64:2070-82.
21. Brieger WR, Okeibunor JC, Abiose AO, Wanji S, Elhassan E, Ndyomugyenyi R,
Amazigo UV: Compliance with eight years of annual ivermectin
treatment of onchocerciasis in Cameroon and Nigeria. Parasit Vectors
2011, 4:152.
22. Gardon J, Gardon-Wendel N, Demanga-Ngangue , Kamgno J, Chippaux JP,
Boussinesq M: Serious reactions after mass treatment of onchocerciasis
with ivermectin in an area endemic for Loa loa infection. Lancet 1997,
350:18-22.
23. Boussinesq M: Loiasis. Ann Trop Med Parasit 2006, 100:715-731.
24. Thomson MC, Obsomer V, Dunne M, Connor SJ, Molyneux DH: Satellite
mapping of Loa loa prevalence in relation to ivermectin use in west and
central Africa. Lancet 2000, 356:1077-8.
25. Takougang I, Meremikwu M, Wandji S, Yenshu EV, Aripko B, Lamlenn SB,
Eka BL, Enyong P, Meli J, Kale O, Remme JH: Rapid assessment method for
prevalence and intensity of Loa loa infection. Bull World Health Organ
2002, 80:852-858.
26. World Health Organisation: Global Programme to Eliminate Lymphatic
Filariasis; Progress Report 2000-2009 and Strategic Plan 2010-2020;
halfway towards eliminating lymphatic filariasis. WHO/HTM/NTD/PCT/
2010.6 Geneva; 2010.
27. Amazigo UV, Brieger WR, Katabarwa M, Akogun O, Ntep M, Boatin B,
N’Doyo J, Noma M, Sékétéli A: The challenges of community directed
treatment with ivermectin (CDTI) within the African Programme for
Onchocerciasis Control (APOC). Ann Trop Med Parasit 2002, 96:S41-S58.
28. The CDI Study Group: Community-directed interventions for priority
health problems in Africa: results of a multicountry study. Bull World
Health Organ 2010, 88:509-518.
29. Homeida M, Braide E, Elhassan E, Amazigo UV, Liese B, Benton B, Noma M,
Etya’alé D, Dadzie KY, Kale OO, Sékétéli A: APOC’s strategy of community-
directed treatment with ivermectin (CDTI) and its potential for providing
additional health services to the poorest populations. African
Programme for Onchocerciasis Control. Ann Trop Med Parasit 2002, 96:
S93-S104.
30. Blackburn BG, Eigege A, Gotau H, Gerlong G, Miri E, Hawley WA, Mathieu E,
Richards F: Successful integration of insecticide-treated bed net
distribution with mass drug administration in Central Nigeria. Am J Trop
Med Hyg 2006, 75:650-655.
31. World Health Organisation: Weekly Epidemiological Record. Global
Programme to Eliminate Lymphatic Filariasis: progress report on Mass
Drug Administration. Wkly Epidemiol Rec 2010, 86:377-388.
32. Taylor-Robinson DC, Jones AP, Garner P: Deworming drugs for treating
soil-transmitted intestinal worms in children: effects on growth and
school performance. Cochrane Database Syst Rev 2007, , 4: CD000371.
33. Miguel E, Kremer M: Worms: Identifying Impacts on Education and Health
in the Presence of Treatment Externalities. Econometrica 2004, 72:159-217.
34. , see D A Bundy presentation at http://ww2.isid.org/Downloads/
NTD2011_Presentations/NTD2011_Bundy.pdf.
35. Millennium Project. Report to the UN Secretary General. 2005. Investing in
Development: A practical plan to achieve the Millennium Development
Goals. 329 pages. United Nations Development Programme. New York;,
ISBN 1-84407-217-7.
36. Nokes C, Grantham- McGregor SM, Sawyer AW, Cooper ES, Robinson BA,
Bundy DAP: Moderate to heavy infections of Trichuris trichiura affect
cognitive function in Jamaican school children. Parasitology 1994,
104:539-547.
37. Alderman , Konde-Lule Joseph, Sebuliba Isaac, Bundy Donald, Hall Andrew:
Effect on weight gain of routinely giving albendazole to preschool
children during child health days in Uganda: cluster randomised
controlled trial. B M J 2006, 333:122-124.
38. Baird S, Hicks JS, Miguel E, Kremer M: Worms at work: long-run impacts of
child health gains. 2011, Working paper available at http://www.
economics.harvard.edu/faculty/kremer/papers_accessed 29 November 2011.
39. Laxminarayan R, Mills AJ, Breman JG, Measham AR, Alleyne G, Claeson M,
Jha P, Musgrove P, Chow J, Shahid-Salles S, Jamison DT: Advancement of
global health: key messages from the Disease Control Priorities Project.
Lancet 2006, 367:1193-208.
40. Bleakely H: Disease and development: evidence from hookworm
eradication in the American South. Quart J Econ 2007, 73-117.
41. World Health Organisation: Leprosy update. Wkly Epidemiol Rec 2011,
86:389-400.
Molyneux and Malecela Parasites & Vectors 2011, 4:234
http://www.parasitesandvectors.com/content/4/1/234
Page 12 of 13
42. World Health Organisation: Dracunculiasis Eradication-global surveillance
summary. Wkly Epidemiol Rec 2010, 86:189-204.
43. World Health Organisation: Working to overcome the global impact of
neglected tropical diseases. Update 2011. WHO/HTM/NTD/2011.3 Geneva;
2011 [http://www.who.int/neglected_diseases].
44. Molyneux D, Hallaj Z, Keusch GT, McManus DP, Ngowi H, Cleaveland S,
Ramos-Jimenez P, Gotuzzo E, Kar K, Sanchez A, Garba A, Carabin H,
Bassili A, Chaignat CL, Meslin FX, Abushama HM, Willingham AL, Kioy D:
Zoonoses and marginalised infectious diseases of poverty: where do we
stand? Parasit Vectors 2011, 4:106.
45. Malecela MN, Kilima P, Mackenzie CD: Implementation and management
of lymphatic filariasis control and elimination programmes: the
Tanzanian experience. In Lymphatic Filariasis: research and control in
eastern and southern Africa.Edited by: Simonsen PE, Malecela MN, Michael
E, Mackenzie CD. DBL- Center for Health Research and Development;
2008:111-123.
46. Mackenzie CD, Mwakitalu E, Mandara WL, Mwingira U, Malecela MN: The
morbidity of lymphatic filariasis in Eastern and Southern Africa. In
Lymphatic Filariasis: research and control in eastern and southern Africa.
Edited by: Simonsen PE, Malecela MN, Michael E, Mackenzie CD. DBL-
Center for Health Research and Development; 59-75.
47. Shenoy RK, Suma TK, Kumaraswami V, Rahmah N, Dhananjayan G, Padma S:
Antifilarial drugs in the doses employed in mass drug administrations
by the Global Programme to Eliminate Lymphatic Filariais; reverse
lymphatic pathology in children with Brugia malayi infection. Ann Trop
Med Parasit 2009, 103:235-247.
48. Tisch DJ, Alexander NDE, Kiniboro B, Dagoro H, Siba PM, Bockarie MJ,
Alpers MP, Kazure JW: Reduction in Acute Filariasis Morbidity during a
Mass Drug Administration Trial to Eliminate Lymphatic Filariasis in
Papua New Guinea. PLoS Negl Trop Dis 2011, 5 e1241.
49. Richter J: The impact of chemotherapy on morbidity due to
schistosomiasis. Acta Trop 2003, 82:161-183.
50. Savioli L, Albonico M, Engels D: Progress in the prevention and control of
schistosomiasis and soil-transmitted helminthiasis. Parasit Int 2004,
53:103-113.
51. Simonsen PE, Pedersen EM, Rwegoshora RT, Malecela MN, Derua YA,
Magesa SM, Lymphatic Filariasis Control in Tanzania: Effect of Repeated
Mass Drug Administration with Ivermectin and Albendazole on infection
and Transmission. PLoS Negl Trop Dis 2010, 4 e696.
52. Gasarasi DB, Premji ZG, Mujinja PGM, Mpembeni R: Acute
adenolymphangitis due to Bancroftian Filariasis in Rufiji District South
East Tanzania. Acta Trop 2000, 75:19-28.
53. Vercruysse J, Behnke JM, Albonico M, Ame SM, Angebault C, Bethony JM,
Engels D, Guillard B, Thi Viet Hoa N, Kang G, Kattula D, Kotze AC,
McCarthy JS, Mekonnen Z, Montresor A, Periago MV, Sumo L, Tchuenté LT,
Thi Cam Thach D, Zeynudin A, Levecke B: Assessment of the Anthelmintic
Efficacy of Albendazole in School Children in Seven Countries Where
Soil-Transmitted Helminths Are Endemic. PloS Negl Trop Dis 2011, 5:e948.
54. Addiss DG: Global elimination of lymphatic filariasis: addressing the
public health problem. Parasit Vectors 2010, 4:741.
55. Osie-Atweneboana MY, Eng JK, Boakye DA, Gyapong JO, Pritchard RK:
Prevalence and intensity of Onchocerca volvulus infection in endemic
communities in Ghana: a two phase epidemiological study. Lancet 2007,
369:2021-2029.
56. Taylor M, Makunde W, McGarry HF, Turner JD, Mand S, Hoerauf A:
Macrofilaricidal activity after doxycycline treatment of Wuchereria
bancrofti: a double blind, randomized placebo controlled trial. Lancet
2005, 365:2116-2121.
57. Taylor M, Hoerauf A, Bockarie M: Lymphatic filariasis and onchocerciasis.
Lancet 2010, 376:1175-1185.
58. Gryseels B: Mass treatment for worms is mistaken. Financial Times 2006.
59. Fenwick A, Rollinson D, Southgate VR: Implementation of Human
Schistosomiasis Control: Challenges and Prospects. Adv Parasit 2006,
61:567-622.
60. Widdus R: Public-private partnerships: an overview. Trans R Soc Trop Med
Hyg 2005, 99:S1-S8.
61. African Programme for Onchocerciasis Control: 15 years of APOC 1995-
2010. WHO/APOC 2011.
62. World Health Organization: Report of the Fifteenth meeting for the WHO
Alliance for the Elimination of Blinding Trachoma by 2020. Geneva 2011
[http://www.who.int/blindness/publications/GET15REPORT4.pdf].
63. Sinuon M, Tsuyuoka R, Socheat D, Montresor A, Palmer K: Financial costs of
deworming children in all primary schools in Cambodia. Trans Roy Soc
Trop Med 2005, 99:664-8.
64. Allotey P, Reidpath DD Pohkrel S: Social Science research in neglected
tropical diseases 1: the ongoing neglect in the neglected tropical
diseases. Hlth Res Pol Syst 2010, 8:32.
65. Parker M, Allen T: Does mass drug administration for the integrated
treatment of neglected tropical diseases really work? Assessing evidence
for the control schistsomiasis and soil transmitted helminths in Uganda.
Hlth Res Pol Syst 2011, 9:3.
66. Kjetland EF, Ndhlovu PD, Gomo E, Mduluza T, Midzi N, Gwanzura L,
Mason PR, Sandvik L, Friis H, Gundersen SG: Association between genital
schistosomiasis and HIV in rural Zimbabwean women. AIDS 2006, 20:594.
67. Marchal B, Van Dormael M, Pirard , Cavalli A, Kegels G, Polman K:
Neglected Tropical Diseases (NTD) control in health systems: The
interface between programmes and general health services. Acta Trop
2011, 120S:S177-S185.
68. Utzinger J, Raso G, Brooker S, de Savigny D, Tanner M, Ornberg G, Singer
B H, N’Goram E K N: Schistosomiasis and Neglected Tropical diseases:
towards integrate and sustainable control and a word of caution.
Parasitology 2009, 136:1859-1874.
69. Molyneux DH, Nantulya V: Public-private partnerships in blindness
prevention: reaching beyond the eye. Eye 2005, 19:1050-6.
70. Ramzy RM, El Setouhy M, Helmy H, Ahmed ES, Abd Elaziz KM, Farid HA,
Shannon WD, Weil GJ: Effect of yearly mass drug administration with
diethylcarbamazine and albendazole on bancroftian filariasis in Egypt: a
comprehensive assessment. Lancet 2006, 367:992-999.
71. Chu BK, Hooper PJ, Bradley MH, McFarland D, Ottesen EA: The economic
benefits resulting from the first 8 years of the Global Programme to
eliminate Lymphatic Filariasis. PLoS Negl Trop Dis 2010, 4:e708.
72. Benton B: Economic impact of onchocerciaiss control through the
African Programme for Onchocerciasis Control: an overview. Ann Trop
Med Parasit 1998, 92:S33-S39.
73. Diawara L, Troare M, Badji A, Issan Y, Doumbia K, Goita SF, Konate L,
Miunkoro K, Sarr MD, Seck AF, Toe L, Toure S, Remme JHF: Feasibility of
onchocerciasis elimination with ivermectin treatment in endemic foci in
Africa: first evidence from studies in Mali and Senegal. PLoS Negl Trop Dis
2009, 3:e497.
74. Gonzalez RJ, Cruz-Ortiz N, Rizzo N, Richards J, Zea-Flores G, Dominguez A,
Sauerbrey M, Catu E, Oliva E, Richards FO, Lindblade KA: Successful
interruption of transmission of Onchocerca volvulus in the Escuintia-
Guatemala Focus, Guatemala. PLoS Negl Trop Dis 2009, 3:e404.
75. Engels D, Wang LY, Palmer K: Control of Schistosomiasis in China. Acta
Trop 2005, 96:67-68.
76. Welburn S, Maudlin I, Simarro P: Controlling Sleeping Sickness-a review.
Parasitology 2009, 136:1943-1949.
77. World Health Organisation: Weekly Epidemiological Record Soil
transmitted helminthiases: estimates of number of children needing PC
and number treated, 2009. Wkly Epidemiol Rec 2011, 86:257-268.
doi:10.1186/1756-3305-4-234
Cite this article as: Molyneux and Malecela: Neglected Tropical Diseases
and the Millennium Development Goals-why the “other diseases”
matter: reality versus rhetoric. Parasites & Vectors 2011 4:234.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Molyneux and Malecela Parasites & Vectors 2011, 4:234
http://www.parasitesandvectors.com/content/4/1/234
Page 13 of 13
